Technology
Health
Biotechnology

NanoViricides

$0.305
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.005 (1.67%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell NanoViricides and other stocks, options, ETFs, and crypto commission-free!

About

NanoViricides Inc., also called NanoViricides, is a development stage company, which engages in the development of nanomedicine drugs against viruses. It focuses on anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs. Read More The company was founded by Anil R. Diwan on July 25, 2000 and is headquartered in Shelton, CT.

Employees
30
Headquarters
Shelton, Connecticut
Founded
2000
Market Cap
21.20M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
167.55K
High Today
$0.3012
Low Today
$0.29
Open Price
$0.2955
Volume
25.75K
52 Week High
$0.8799
52 Week Low
$0.196

Collections

Technology
Health
Biotechnology
Therapy
Medical
US
North America

News

PR NewswireMar 12

NanoViricides Reports Successful Completion of Another Important Safety Study towards an IND

SHELTON, Conn., March 12, 2019 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") a company with novel platform technology to treat difficult and life-threatening viral diseases, announces that its first drug candidate has successfully completed another important step in its Safety/Toxicology studies moving towards human clinical trials. The broad-spectrum anti-herpes clinical candidate in the HerpeCide™ program, namely NV-HHV-101, was tested in this study, formulated as a subcutaneous in...

371
MarketBeatMar 7

Stock Price, News, & Analysis for NanoViricides

NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candid...

85
Seeking AlphaMar 5

NanoViricides reports positive early-stage data on broad-spectrum drug candidate; shares up 45% premarket

NanoViricides' (NYSEMKT:NNVC) has successfully completed the first safety/toxicology studies evaluating broad-spectrum drug candidate NV-HHV-101, a topical cream formulation, in mini-pigs.

538

Earnings

-$0.04
-$0.03
-$0.01
$0.00
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected May 21, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.